Nebulized antibiotics in cystic fibrosis

Pediatric Drugs

Volumn 4, Issue 7, 2002, Pages 455-467

  Sermetgaudelus, I ^a   Lecocguic, Y ^b   Ferroni, A ^a   Clairicia, M ^a   Barthe, J ^a   Delaunay, J ^a   Brousse, V ^a   Lenoir, G ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b AMERICAN HOSPITAL OF PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CARBENICILLIN; CEFALORIDINE; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; FLUCLOXACILLIN; GENTAMICIN; PLACEBO; TICARCILLIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

AEROSOL; ASPERGILLUS FUMIGATUS; BACTERICIDAL ACTIVITY; BREATHING; BRONCHITIS; BRONCHOSPASM; BURKHOLDERIA CEPACIA; CHILD; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG MECHANISM; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; NEBULIZATION; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY FUNCTION; REVIEW; STAPHYLOCOCCUS AUREUS; CLINICAL TRIAL; COMMUNICABLE DISEASE; METABOLISM; METHODOLOGY; NEBULIZER; STATISTICS;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; COMMUNICABLE DISEASES; CYSTIC FIBROSIS; HUMANS; NEBULIZERS AND VAPORIZERS;

EID: 0035985752     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204070-00004     Document Type: Review

References (80)

1. Pathogenicity of microbes associated with cystic fibrosis
2. Evidence for using nebulised antibiotics in cystic fibrosis
3. Drug therapy: Management of pulmonary disease in patients with cystic fibrosis
4. Inhalation of antibiotics in cystic fibrosis
5. Droplet size disposition of nebulised aerosols for inhalation therapy
6. Technical report: Precautions regarding the use of aerosolized antibiotics
7. Therapeutic aerosols I: Physical and practical considerations
8. Physical properties of antibiotic aerosols produced by jet and ultrasonic nebulizers
9. A comparison of the availability of tobramycin for inhalation from vented vs unvented nebulizers
10. Evaluation of jet nebulizers for use of gentamicin solution
11. Why do medical nebulizers differ in their output and particle size characteristics
12. Aerosol delivery in in ranis and young children
13. Measurement of bronchial hyperreactivity in infants and preschool children using a new method
14. Drug delivery from jet nebulizers
15. How should aerosolized drug doses be size-corrected for children of different sizes
16. The carbenicillin potentiating effect of N-acetyleysteine in vitro
17. Recombinant human Dnase 1 reduces the viscosity of cystic fibrosis sputum
18. Quantitative deposition of aerosolized gentamycin in cystic fibrosis
19. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis
20. Homogeneity of bronchopulmonary distribution of 99m Tc aerosol in normal subject and in cystic fibrosis patients
21. Radioaerosol assessment of lung improvement in cystic fibrosis patients treated for acute pulmonary exacerbations
22. Mucociliary clearance in patients with cystic fibrosis and in normal subjects
23. Bioactivity of gentamycin in purulent sputum from patients with cystic fibrosis or bronchiectasis: Comparison with activity in serum
24. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum
25. Pharmacokinetics of antibiotics in the lung
26. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
27. Deposition of aerosol in the respiratory tract
28. Aerosolized tobramycin pharmacokinetics in cystic fibrosis patients
29. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems
30. Aerosol administration of antibiotics
31. Inhaled antibiotics in cystic fibrosis
32. Long term tobramycin aerosol therapy in cystic fibrosis
33. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis
34. Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation
35. Aerosol carbenicillin and gentamycin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis
36. Antibiotic prophylaxis in cystic fibrosis: Inhaled cephaloridine as an adjunct to cloxacillin
37. Nebulized gentamicin in children and adolescents with cystic fibrosis
38. A controlled trial of aminoglycoside and oral flucloxacillin versus placebo in the out-patient management of children with cystic fibrosis
39. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis
40. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
41. Long term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa
42. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
43. Nebulized antipseudomonal antibiotic therapy in cystic fibrosis: A meta-analysis of benefits and risk
44. Aerosolized amikacin administration to cystic fibrosis patients chronically infected with Pseudomonas aeruginosa
45. Carbenicillin in patients with cystic fibrosis: Clinical pharmacology and therapeutic evaluation
46. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis
47. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis
48. Nehulized colomycin for early pseudomonas colonization in cystic fibrosis
49. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment
50. Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis
51. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration in pulmonary function with cystic fibrosis
52. Interest of inhaled antibiotics for treatment of first colonization by Pseudomonas aeruginosa in cystic fibrosis
53. Comparison of intravenous and inhalation antibiotic therapy in acute pulmonary deterioration in cystic fibrosis
54. Efficacy of inhaled tobramycin in cystic fibrosis
55. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations
56. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations
57. Bronchial response to nebulized antibiotics in children with cystic fibrosis
58. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis
59. Nebulized colistin causes chest tightness in adults with cystic fibrosis
60. Comparison of efficacy of salbutamol and sodium cromoglycate in the prevention of ticarcillin-induced bronchoconstriction
61. Assessment of potential ototoxicity following bigb-dose nebulized tobramycin in patients with cystic fibrosis
62. Aerosol polymyxin and pneumonia in seriously ill patients
63. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients
64. Survival of Stenotrophomonas maltophilia following exposure to concentrations of tobramycin used in aerosolized therapy for cystic fibrosis patients
65. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
66. A national survey of nebuliser use
67. Nosocomial outbreak of Pseudomonas cepacia associated with contamination of reusable electronic ventilator temperature probes
68. Home-use nebulizers: A potential primary source of Burkholderia cepacia and other colistin-resistant, gram-negative bacteria in patients with cystic fibrosis
69. Case control and vector studies of nosocomial acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis
70. Pseudomonas cepacia in in-patients with cystic fibrosis
71. Histologic changes in the respiratory tract induced by inhalation of xenobiotics: Physiologic adaptation or toxicity
72. Long-term benefit of inhald tobramycin in adolescent patients with cystic fibrosis
73. Aerosolized vancomycin for the treatment of airway colonization by methicittin-resistant Staphylococcus aureus
74. Aerosolized vancomycin therapy facilitating nursing home placement
75. Aerosolized vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infection in cystic fibrosis
76. Model of recurrent pulmonary aspergillosis in rats
77. Prophylactic efficacy of aerosolized liposomal (Ambisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis
78. In vitro suppression of Pseudomonas ceparia after limited exposure to subinbibitory concentrations of amiloride and 5-(N,N-hexamethylene) amiloride